Pomalidomide-C7-COOH

Background Introduction

Pomalidomide-C7-COOH is a bifunctional molecule specially designed for next-generation PROTAC (Proteolysis Targeting Chimera) and targeted protein degradation applications. As a derivative of pomalidomide—a well-known ligand for the E3 ubiquitin ligase cereblon (CRBN)—this product features an extended C7 aliphatic linker and a carboxylic acid functional group. Its structure enables flexible PROTAC design and improved pharmacokinetic profiles, making it a high-value building block for drug discovery.

Mechanism

The mechanism of Pomalidomide-C7-COOH centers on its ability to recruit the CRBN E3 ubiquitin ligase. When conjugated to a target protein ligand via its reactive carboxylic acid group, it forms part of a PROTAC molecule. The PROTAC simultaneously binds the target protein and CRBN, positioning them in proximity. This induces ubiquitination of the target protein, marking it for selective proteasomal degradation. This catalytic event results in efficient and sustained reduction of the disease-relevant protein.

Applications

Pomalidomide-C7-COOH is widely utilized as an E3 ligase ligand-linker conjugate in the synthesis of custom PROTACs and targeted protein degraders. Its distinct structure with a C7 linker enables optimal spatial arrangement between the E3 ligase and target proteins, making it ideal for drug discovery, preclinical research, and chemical biology studies. Researchers leverage Pomalidomide-C7-COOH to facilitate the development of novel therapeutics against cancer, neurodegenerative disorders, and other diseases involving dysregulated proteins.

Pomalidomide-C7-COOH serves as a crucial component in the development of PROTACs, facilitating targeted protein degradation through its role as an E3 Ligase Ligand-Linker Conjugate. It offers a versatile platform for exploring the mechanistic pathways of protein degradation. The following provides a detailed description of this molecule's linker, ligand, and selection of target protein ligands.

Linker: The linker in Pomalidomide-C7-COOH is characterized by a seven-carbon chain, providing moderate flexibility to accommodate various spatial orientations. Its non-cleavable nature ensures stability, making it suitable for applications requiring prolonged interaction between the ligand and the target protein.

Ligand: The ligand component is based on pomalidomide, a thalidomide derivative known for its high affinity to the cereblon E3 ubiquitin ligase. This structural characteristic ensures effective recruitment of the E3 ligase complex, enhancing the efficacy of the protein degradation process.

Reactive Site: The reactive site of Pomalidomide-C7-COOH is the carboxylic acid group, which is poised for conjugation with target protein ligands. Recommended reaction types for this site include amide bond formation or esterification, facilitating stable and effective linkage to the target protein warhead.

Recommended Target Protein Ligand: The ideal warhead for Pomalidomide-C7-COOH is a small molecule with a functional group capable of forming a covalent bond with the carboxylic acid moiety. This compatibility allows for precise targeting of proteins of interest, offering advantages in studying protein function and degradation pathways. Such applications are pivotal in elucidating disease mechanisms and exploring potential therapeutic strategies.